Authors
Latest:
Emerging Adulthood: From Adolescent to Attending PhysicianFaced with a persistent question from her teenage years, Elaine Chang, MD, may have come up with an answer.
Latest:
Elaine Mardis on Sensitivity to Aromatase InhibitorsElaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors
Latest:
Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLCElaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.
Latest:
Dr. Walker on the Use of Radiation Therapy in Patients With Breast CancerEleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.
Latest:
Electra D. Paskett, PhD, on Cervical Cancer ScreeningElectra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.
Latest:
Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open HysterectomiesEleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.
Latest:
Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast CancersTerry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.
Latest:
Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast CancerTerry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.
Latest:
Dr. Lukina Discusses Timely Gaucher Disease DiagnosisDr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis
Latest:
Dr. Andreopoulou on the Impact of Immunotherapy in TNBCEleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.
Latest:
Antibody-Drug Conjugates and T-DM1Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression
Latest:
Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in OsteosarcomaElham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.
Latest:
Dr. Diamond on the Ability to Test Urine for BRAF MutationsEli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation
Latest:
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment LandscapeFollowing the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Latest:
Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic LeukemiaIbrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
Latest:
Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast CancerElias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.
Latest:
Dr. Estey Discusses the FDA Approval ProcessElihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin).
Latest:
Dr. Chan on Improving Mammography Screening Rates With Signed LettersElisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.
Latest:
Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast CancerElisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.
Latest:
IO Therapy in mCRPC and Clinical PearlsBefore sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Latest:
Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer CenterThe Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.
Latest:
Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast CancerElisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.
Latest:
Dr. Engel on the Future of Eltrombopag in HIV-Related ThrombocytopeniaElissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.
Latest:
Androgen Deprivation Therapy and Cardiovascular Risk in Prostate CancerAccumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association
Latest:
Preparing for the Job SearchBefore you even contact a physician recruiter, respond to a posted position, or network your contacts for leads, you need to know which factors are important to you in finding the position that meets your goals
